GLP-1 Receptor Agonists in Research: From Semaglutide to Next-Generation Dual and Triple Agonists

Introduction

Glucagon-like peptide-1 (GLP-1) receptor agonists represent one of the most significant advances in metabolic research of the past two decades. What began as a treatment for type 2 diabetes has evolved into a broad research platform spanning obesity, cardiovascular disease, neurodegeneration, and now longevity. The class has expanded from first-generation compounds with modest efficacy to next-generation dual and triple agonists capable of producing weight reductions previously achievable only through bariatric surgery.

This article traces the scientific evolution of GLP-1 receptor agonist research, from the discovery of native GLP-1 through the current generation of multi-receptor agonists, with a focus on the mechanisms, clinical trial data, and emerging research directions that define the field in 2026.

The Biology of GLP-1

Glucagon-like peptide-1 is an incretin hormone secreted by L-cells in the distal small intestine and colon in response to nutrient ingestion. It was first characterized in the 1980s through studies of the proglucagon gene, which encodes both glucagon and the GLP-1 precursor.

Native GLP-1 exerts its effects through the GLP-1 receptor (GLP-1R), a class B G protein-coupled receptor expressed in the pancreas, brain, heart, kidney, and gastrointestinal tract. Its primary physiological actions include:

- Glucose-dependent insulin secretion: GLP-1 stimulates insulin release from pancreatic beta cells only in the presence of elevated glucose, providing an inherent safety mechanism against hypoglycemia - Glucagon suppression: GLP-1 inhibits glucagon secretion from alpha cells, reducing hepatic glucose output - Gastric emptying delay: GLP-1 slows gastric emptying, reducing postprandial glucose excursions - Central appetite regulation: GLP-1 receptors in the hypothalamus and brainstem mediate satiety signaling, reducing food intake

Native GLP-1 has a plasma half-life of approximately 2 minutes due to rapid degradation by dipeptidyl peptidase-4 (DPP-4) and renal clearance, making it unsuitable as a therapeutic agent in its native form. This limitation drove the development of DPP-4-resistant analogs.

First-Generation GLP-1 Receptor Agonists

Exenatide (Byetta/Bydureon)

Exenatide, derived from the Gila monster peptide exendin-4, was the first GLP-1 receptor agonist approved for clinical use (2005). It shares approximately 53% sequence homology with native GLP-1 and is resistant to DPP-4 degradation. Initial twice-daily formulations were followed by once-weekly extended-release versions (Bydureon).

Liraglutide (Victoza/Saxenda)

Liraglutide (2010) introduced a key innovation: fatty acid conjugation to albumin, extending the half-life to approximately 13 hours and enabling once-daily dosing. At the higher dose approved for obesity (3 mg), liraglutide (Saxenda) produced mean weight reductions of approximately 5-8% in clinical trials -- meaningful but modest compared to what followed.

The Semaglutide Revolution

Semaglutide (Ozempic/Wegovy) represented a step-change in GLP-1 research. Two structural modifications -- a C18 fatty diacid chain enabling strong albumin binding and two amino acid substitutions -- extended the half-life to approximately 165-184 hours, enabling once-weekly subcutaneous dosing.

The STEP clinical trial program demonstrated weight reductions of 14.9% at 68 weeks with 2.4 mg weekly semaglutide (STEP 1), with 86.4% of participants achieving at least 5% weight loss. These results, published in the New England Journal of Medicine in 2021, fundamentally changed the landscape of obesity research and treatment.

Cardiovascular outcomes data from the SELECT trial (2023) further demonstrated a 20% reduction in major adverse cardiovascular events (MACE) in patients with obesity and established cardiovascular disease -- establishing GLP-1 agonism as a cardioprotective mechanism independent of glucose lowering.

Dual Agonism: Tirzepatide (GLP-1/GIP)

Tirzepatide (Mounjaro/Zepbound) introduced the concept of dual receptor agonism, simultaneously activating both GLP-1R and the glucose-dependent insulinotropic polypeptide receptor (GIPR). This approach was based on research suggesting that GIP and GLP-1 have complementary and synergistic effects on metabolic regulation.

The SURMOUNT-1 trial demonstrated mean weight reductions of 20.9% at 72 weeks with the 15 mg dose -- surpassing semaglutide and approaching the efficacy of bariatric surgery. The SURPASS cardiovascular outcomes trial (SURPASS-CVOT) further established tirzepatide's cardiovascular benefits.

The success of tirzepatide validated the multi-receptor agonism strategy and accelerated development of the next generation.

Triple Agonism: Retatrutide (GLP-1/GIP/GCG)

Retatrutide (LY3437943) adds glucagon receptor (GCGR) agonism to the GLP-1/GIP combination. Glucagon receptor activation increases energy expenditure through thermogenesis and hepatic fat oxidation, theoretically addressing the metabolic adaptation (reduced energy expenditure) that limits weight loss with GLP-1 monotherapy.

Phase 2 TRIUMPH trial data (2023) showed mean weight reductions of 24.2% at 48 weeks with the highest dose -- the largest weight reduction ever reported in a randomized controlled trial of a pharmacological agent. Phase 3 trials are ongoing as of 2026.

The Amylin Combination: CagriSema

CagriSema pairs semaglutide with cagrilintide, a long-acting amylin analog. Amylin is a pancreatic hormone co-secreted with insulin that regulates gastric emptying, glucagon secretion, and satiety through central mechanisms distinct from GLP-1 pathways. The combination targets complementary satiety circuits.

The REDEFINE 1 trial (2024) reported mean weight reductions of 22.7% at 68 weeks -- comparable to retatrutide and significantly exceeding semaglutide monotherapy. The distinct mechanism (amylin vs. glucagon) may offer advantages in specific patient populations.

Comparative Overview of GLP-1 Class Research Compounds

| Compound | Receptors | Peak Weight Reduction | Trial Program | Status (2026) | |---|---|---|---|---| | Liraglutide | GLP-1R | ~8% | SCALE | Approved | | Semaglutide | GLP-1R | ~15% | STEP | Approved | | Tirzepatide | GLP-1R + GIPR | ~21% | SURMOUNT | Approved | | Retatrutide | GLP-1R + GIPR + GCGR | ~24% | TRIUMPH | Phase 3 | | CagriSema | GLP-1R + Amylin | ~23% | REDEFINE | Phase 3 |

Emerging Research Directions

Beyond weight management, GLP-1 receptor agonist research has expanded into several areas of significant scientific interest:

Neurodegeneration: GLP-1 receptors are expressed throughout the brain, and preclinical studies have demonstrated neuroprotective effects in models of Parkinson's and Alzheimer's disease. Clinical trials of semaglutide in Parkinson's disease are ongoing (SPARK trial).

Non-alcoholic steatohepatitis (NASH/MASH): Semaglutide has demonstrated histological improvement in NASH in Phase 2 trials, and resmetirom (a thyroid hormone receptor beta agonist) has been approved for MASH -- establishing the liver as a key target for metabolic interventions.

Addiction and reward pathways: Preclinical and early clinical data suggest GLP-1 agonists may reduce cravings for alcohol, nicotine, and other substances through effects on mesolimbic dopamine pathways.

Longevity research: The intersection of metabolic health, cardiovascular protection, and potential neuroprotection has positioned GLP-1 agonists as candidate longevity compounds, with several research groups investigating their effects on biological aging markers.

References

1. Drucker DJ. "The biology of incretin hormones." Cell Metabolism. 2006;3(3):153-165. https://pubmed.ncbi.nlm.nih.gov/16517403/
2. Wilding JPH, et al. "Once-weekly semaglutide in adults with overweight or obesity." New England Journal of Medicine. 2021;384(11):989-1002. https://pubmed.ncbi.nlm.nih.gov/33567185/
3. Jastreboff AM, et al. "Tirzepatide once weekly for the treatment of obesity." New England Journal of Medicine. 2022;387(3):205-216. https://pubmed.ncbi.nlm.nih.gov/35658024/
4. Jastreboff AM, et al. "Triple hormone receptor agonist retatrutide for obesity." New England Journal of Medicine. 2023;389(6):514-526. https://pubmed.ncbi.nlm.nih.gov/37366315/
5. Lincoff AM, et al. "Semaglutide and cardiovascular outcomes in obesity without diabetes." New England Journal of Medicine. 2023;389(24):2221-2232. https://pubmed.ncbi.nlm.nih.gov/37952131/

This article is intended for educational and laboratory reference purposes only. All research must comply with applicable institutional, local, and national regulations. This content does not constitute medical advice.

See Also: For a mechanistic deep dive, see GLP-1 Receptor Agonism: Mechanism of Action Deep Dive. For a brand-level comparison, see Ozempic vs. Wegovy vs. Mounjaro: A Research Comparison.